Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) launched the “Won’t Lose” media campaign on May 4, 2026, timed ahead of FIFA World Cup 2026™ to spotlight the company’s commitment to advancing breakthrough medicines for patients.
Assets feature narration by Ali Krieger and run across CTV, programmatic display, streaming audio, video and social media; campaign creative and a full transcript are available at www.BMSWontLose.com.
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2026 financial results and provided investor access details. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on April 30, 2026. A replay will be available about three hours after the call.
Investors can view the detailed earnings press release and presentation on the company’s Investor Relations website and access contact emails for media and investor relations.
Bristol Myers Squibb (BMY) and Pfizer announced that Eliquis (apixaban) will be sold on Mark Cuban Cost Plus Drug Company starting April 27, 2026, offering a 30-day supply for a total cash price of $345. The move expands direct-to-patient access for cash-paying customers alongside the existing Eliquis 360 Support option.
The announcement reiterates Eliquis indications for AFib, DVT/PE, and post-orthopedic surgery, and includes Important Safety Information about bleeding risks and use limitations.
Atrium Therapeutics (Nasdaq: RNA) announced it earned a $15 million development milestone from Bristol Myers Squibb (NYSE: BMY) after delivering a development candidate for a cardiology indication under their global collaboration.
Under the deal Atrium is eligible for up to $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits; Bristol Myers Squibb will fund future clinical development, regulatory, and commercialization activities.
Foundation Medicine expanded its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne CDx as a next-generation sequencing companion diagnostic to identify patients with homozygous MTAP deletion across multiple indications for an investigational targeted therapy.
FoundationOne CDx is an FDA-approved tissue-based NGS test able to detect copy number loss; the release highlights copy number calling challenges due to low signal-to-noise and emphasizes the test’s ability to report homozygous deletion to help match patients to targeted therapies.
Bristol Myers Squibb (NYSE: BMY) announced an evolution and expansion of its Standing in the Gaap program to advance more equitable multiple myeloma care. The program will launch one of the largest U.S. multiple myeloma surveys, engaging >1,000 patients, caregivers and providers.
The survey, developed with leading advocacy groups, builds on a decade of activity since 2016, including >50 educational programs, ~5,000 attendees and a digital community of nearly 60,000, to translate lived experience into community-informed action.
Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 SCOUT-HCM results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy on March 29, 2026. The trial met its primary endpoint with an LS mean Valsalva LVOT gradient reduction of −48.0 mm Hg at Week 28 (P < 0.0001).
Camzyos showed improvements in resting and post-exercise gradients, maximal LV wall thickness, diastolic function (E/e'), and NYHA class versus placebo; safety was similar to adults with no LVEF <50% observed during 28 weeks.
Bristol Myers Squibb (NYSE: BMY) reported Phase 4 data showing symptom stability when switching adults with schizophrenia from oral atypical antipsychotics to Cobenfy (xanomeline and trospium chloride) over 8 weeks.
Key findings: ~86% completed treatment, no discontinuations for lack of efficacy, mean PANSS changes −4.2 (4-week taper) and −3.1 (2-week taper), 49% experienced ≥1 TEAE with no serious TEAEs, and tolerability consistent with prior EMERGENT trials.
Viz.ai will present three abstracts on Viz HCM, its AI-ECG solution within the Viz Cardio Suite, at ACC.26 (March 28–30, 2026).
Key findings include 11 new real-world HCM diagnoses, 13% progression from AI-positive/phenotype-negative over 2.74 years, and that Viz HCM is the first FDA-cleared AI algorithm for HCM detection from a standard 12-lead ECG. The tool was developed under a multi-year agreement with Bristol Myers Squibb (NYSE: BMY).
insitro expanded its ALS collaboration with Bristol Myers Squibb (NYSE: BMY) by adding two targets, ALS-2 and ALS-3, joining ALS-1 (nominated Dec 2024). insitro will advance an oligonucleotide for ALS-1 while BMY progresses a small molecule; insitro received a $10 million milestone.
Using its Virtual Human™ platform, insitro identified targets linked to TDP-43 mislocalization (~97% of ALS) and showed in iPSC-derived motor neurons rescue of neurite growth and reduction of cryptic exons.